https://interactions.guidetherapeutiquevih.com/en/interaction-details?id=19452
https://interactions.guidetherapeutiquevih.com/en/interaction-details?id=19452
Document made available to the pharmacist to communicate a drug interaction to the doctor.
DOWNLOADGlecaprevir / Pibrentasvir can inhibit the metabolism (CYP 3A4) and increase the plasma concentration of Fentanyl.
–
–
–
Possible increased risk of opioids toxicity.
Avoid association, if possible.
If deemed necessary, a decrease in the dose and/or close monitoring is recommended.
The product monograph recommends avoiding the combination with drugs that are CYP3A4 inhibitors.
See comments for further details.
Morphine and hydromorphone.
Signs and symptoms of opioid toxicity miosis, euphoria, dysphoria, drowsiness, confusion, excessive sedation, decreased alertness, hallucinations, dizziness, bradycardia, myoclonus, hypotension, prolonged or recurrent respiratory depression.
–
–
Ref #3373 : Glecaprevir/pibrentasvir is a weak inhibitor of CYP 3A4. Administration with midazolam did not show a clinically significant increase.
Administration with fentanyl has not been studied, but since fentanyl has a narrow therapeutic index, concomitant use especially with illicit fentanyl use could have serious consequences for the patient. Indeed, high concentrations of fentanyl following drug interactions are associated with a risk of respiratory distress and death.